146 related articles for article (PubMed ID: 16941344)
1. Measles-virus-neutralizing antibodies in intravenous immunoglobulins.
Audet S; Virata-Theimer ML; Beeler JA; Scott DE; Frazier DJ; Mikolajczyk MG; Eller N; Chen FM; Yu MY
J Infect Dis; 2006 Sep; 194(6):781-9. PubMed ID: 16941344
[TBL] [Abstract][Full Text] [Related]
2. Correlation between the results of two analytical methods for measuring measles virus neutralizing antibodies in source plasma and therapeutic immunoglobulin products.
Hong J; Kim D; Won Y; Yoon J; Park KJ; Oh J; Kim CW
Biologicals; 2019 May; 59():20-28. PubMed ID: 30992162
[TBL] [Abstract][Full Text] [Related]
3. Measles virus neutralizing antibodies in immunoglobulin lots produced from plasma collected in Europe or the United States.
Farcet MR; Karbiener M; Rabel PO; Schirmer A; Ilk R; Kreil TR
Vaccine; 2019 May; 37(24):3151-3153. PubMed ID: 31060953
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin.
Planitzer CB; Farcet MR; Schiff RI; Ochs HD; Kreil TR
J Med Virol; 2011 Feb; 83(2):305-10. PubMed ID: 21181927
[TBL] [Abstract][Full Text] [Related]
5. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.
LeBaron CW; Beeler J; Sullivan BJ; Forghani B; Bi D; Beck C; Audet S; Gargiullo P
Arch Pediatr Adolesc Med; 2007 Mar; 161(3):294-301. PubMed ID: 17339511
[TBL] [Abstract][Full Text] [Related]
6. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination.
Cohen BJ; Doblas D; Andrews N
Vaccine; 2008 Nov; 26(50):6392-7. PubMed ID: 18834911
[TBL] [Abstract][Full Text] [Related]
7. Measles-specific neutralizing antibodies in rural Mozambique: seroprevalence and presence in breast milk.
Mandomando IM; Naniche D; Pasetti MF; Vallès X; Cuberos L; Nhacolo A; Kotloff KL; Martins H; Levine MM; Alonso P
Am J Trop Med Hyg; 2008 Nov; 79(5):787-92. PubMed ID: 18981523
[TBL] [Abstract][Full Text] [Related]
8. [Distribution of neutralizing measles serum antibodies according to age in women of childbearing age in France in 2005-2006].
Gagneur A; Pinquier D; Aubert M; Soubeyrand B; Balu L; Brissaud O; Gras-Le-Guen C; Hau-Rainsard I; Mory O; Picherot G; De Pontual L; Stephan JL; Reinert P
Arch Pediatr; 2008 Oct; 15(10):1525-30. PubMed ID: 18804979
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia.
Goldsmith JC; Eller N; Mikolajczyk M; Manischewitz J; Golding H; Scott DE
Vox Sang; 2004 Feb; 86(2):125-9. PubMed ID: 15023182
[TBL] [Abstract][Full Text] [Related]
10. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay.
Cohen BJ; Parry RP; Doblas D; Samuel D; Warrener L; Andrews N; Brown D
J Virol Methods; 2006 Feb; 131(2):209-12. PubMed ID: 16188328
[TBL] [Abstract][Full Text] [Related]
11. Measles Virus Neutralizing Antibodies in Intravenous Immunoglobulins: Is an Increase by Revaccination of Plasma Donors Possible?
Modrof J; Tille B; Farcet MR; McVey J; Schreiner JA; Borders CM; Gudino M; Fitzgerald P; Simon TL; Kreil TR
J Infect Dis; 2017 Nov; 216(8):977-980. PubMed ID: 28968738
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the neutralizing and ELISA antibody titres to measles virus in human sera and in gamma globulin preparations.
Rabenau HF; Marianov B; Wicker S; Allwinn R
Med Microbiol Immunol; 2007 Sep; 196(3):151-5. PubMed ID: 17308917
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins.
Modrof J; Berting A; Tille B; Klotz A; Forstner C; Rieger S; Aberham C; Gessner M; Kreil TR
Transfusion; 2008 Jan; 48(1):178-86. PubMed ID: 17900278
[TBL] [Abstract][Full Text] [Related]
14. Development of a new neutralization test for measles virus.
Fujino M; Yoshida N; Kimura K; Zhou J; Motegi Y; Komase K; Nakayama T
J Virol Methods; 2007 Jun; 142(1-2):15-20. PubMed ID: 17320979
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of an automatable focus reduction neutralisation test for the detection of measles virus antibodies using imaging analysis.
Terletskaia-Ladwig E; Enders G; Meier S; Dietz K; Enders M
J Virol Methods; 2011 Dec; 178(1-2):124-8. PubMed ID: 21939689
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to hepatitis A virus in immune serum globulin.
Smallwood LA; Tabor E; Finlayson JS; Gerety RJ
J Med Virol; 1981; 7(1):21-7. PubMed ID: 7241098
[TBL] [Abstract][Full Text] [Related]
17. Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization.
de Swart RL; Yüksel S; Osterhaus AD
J Virol; 2005 Sep; 79(17):11547-51. PubMed ID: 16103210
[TBL] [Abstract][Full Text] [Related]
18. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005.
Atrasheuskaya AV; Kulak MV; Neverov AA; Rubin S; Ignatyev GM
Vaccine; 2008 Apr; 26(17):2111-8. PubMed ID: 18343536
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
20. A serosurvey to identify the window of vulnerability to wild-type measles among infants in rural Mali.
Tapia MD; Sow SO; Medina-Moreno S; Lim Y; Pasetti MF; Kotloff K; Levine MM
Am J Trop Med Hyg; 2005 Jul; 73(1):26-31. PubMed ID: 16014826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
